Panbela Therapeutics Inc's Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including healthcare benefit programs such as Medicare, Medicaid, and the Children’s Health Insurance Program. Its clients include manufacturers of drugs, devices, biological products, and medical supplies that receive payments under these programs. Additionally, the company works with physicians, specified healthcare professionals, teaching hospitals, and designated entities or individuals as recipients of payments or transfers of value. The market segments served include federal and state healthcare programs as well as private third-party payors.
Panbela Therapeutics, a clinical stage biopharmaceutical company, has made significant strides in developing disruptive therapeutics for patients with urgent unmet medical needs. Their latest achievement involves the evaluation of the safety and efficacy of Eflornithine (Difluoromethylornithine, DFMO) in patients with gastric premalignant conditions in high incidence areas of Latin America.Panbela Therapeutics ongoing collaboration with Vanderbilt University Medical Center has resulted in the acceptance of an abstract for eflornithine at the prestigious Digestive Disease Week (DDW) conference. The abstract submission signifies the recognition of Panbela s pioneering work in the field of polyamine synthesis ...
Eflornithine (DFMO): A Promising Breakthrough in Cancer Treatment to be Presented at Digestive Disease Week ConferenceMinneapolis, April 30, 2024 - Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company specializing in disruptive therapeutics for cancer treatment, has announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the upcoming Digestive Disease Week (DDW) conference. This groundbreaking research is the result of Panbela Therapeutics ongoing collaboration with the esteemed Vanderbilt University Medical Center.The acceptance of eflornithine abstract for an oral presentation at DDW, scheduled for May ...
Panbela Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal programs for products, including healthcare benefit programs such as Medicare, Medicaid, and the Children’s Health Insurance Program. Its clients include manufacturers of drugs, devices, biological products, and medical supplies that receive payments under these programs. Additionally, the company works with physicians, specified healthcare professionals, teaching hospitals, and designated entities or individuals as recipients of payments or transfers of value. The market segments served include federal and state healthcare programs as well as private third-party payors.
Sources:
Panbela Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Panbela Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Panbela Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
